Industry Experts

Olivier Nolan‑Stevaux leads a talented team within Gilead’s Oncology Research in Foster City, California, focused on Targeted Biologics. His scientific journey includes academic research at MGH Cancer Center and UCSF and industry research at Amgen. In the past three years, his team initiated internal T cell engager (TCE) projects and research collaborations aimed at novel cancer targets (Cartography), dual-targeting TCEs (Merus), targeted agonistic Biologics (Macrogenics, Tentarix), and next-generation ADCs (Tubulis). Prior to Gilead, his work at Amgen focused on combination approaches for TCEs and the development of Xaluritamig, the first STEAP1-targeted TCE (Xencor collaboration), now in Phase 3 for prostate cancer.